1. The combination of a) a compound of formula Ia: or a pharmaceutically acceptable salt thereof and b) abiraterone or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of hyperproliferative disorder. The combination of claim 1, wherein the hyperproliferative disorder is cancer. The combination of claim 2, wherein the cancer is associated with a PTEN mutation. The combination of claim 2, wherein the cancer is associated with a mutation, overexpression, or amplification of AKT. 5. The combination of claim 2, wherein the cancer is associated with a PI3K.6 mutation. The combination of claim 2, wherein the cancer is associated with a Her2 / ErbB2.7 mutation. A combination according to any one of claims 2 to 6, wherein the cancer is selected from breast, lung, ovary, prostate, melanoma, stomach, colon, kidney, head and neck cancer, and glioma. The combination according to any one of claims 1 to 6, wherein the combination provides a synergistic effect in the treatment of hyperproliferative disorder. The combination of claim 8, where the value of the combinatorial index of the synergistic effect is less than approximately 0.8.10. A compound of formula Ia or a pharmaceutically acceptable salt thereof, as defined in claim 1, for therapeutic use in order to improve the quality of life of a patient who is being treated for a hyperproliferative disorder using abiraterone or a pharmaceutically acceptable salt thereof. 11. A method for treating a hyperproliferative disorder in a mammal, comprising administering to the mammal a combination of a) a compound of formula Ia: or a pharmaceutically acceptable salt thereof； and b) abiraterone or a pharmaceutically acceptable salt thereof. 12. The use of a compound of formula Ia or a pharmaceutically acceptable salt thereof, as defined in claim 1, for the manufacture of a medicament1. Комбинация a) соединения формулы Ia:или его фармацевтически приемлемой соли и b) абиратерона или его фармацевтически
